India’s growing stature as a global manufacturing hub for next-generation biologics took centre stage at BioAsia 2026, where industry leaders emphasised the country’s ability to scale advanced therapies—from vaccines and RNA platforms to cell and gene therapies. During a high-level panel discussion on advanced therapies, experts emphasized that biologics innovation today depends on more than just breakthrough science. Vaccine Leadership and Global AmbitionRaches Ella, Chief Development Officer at Bharat Biotech, highlighted India’s pivotal contribution to global immunisation. Today, Ireland produces biologic medicines worth €100 billion annually, making it one of the largest global manufacturing bases in this segment. Biologics FutureOverall, the BioAsia 2026 discussion reinforced a clear message: India is no longer just a cost-efficient manufacturing base—it is evolving into a strategic partner in global biologics innovation.

Source: The Hindu February 20, 2026 13:49 UTC